Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US

References

• GarberAJAbrahamsonMJBarzilayJIAACE/ACE comprehensive diabetes management algorithmEndocr Pract201521443844725877012
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJMManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care201538114014925538310
   PubMed Web of Science ®Google Scholar
• HeineRJVan GaalLFJohnsDExenatide versus basal insulin in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med2005143855956916230722
   PubMed Web of Science ®Google Scholar
• RiddleMCRosenstockJGerichJInsulin Glargine 4002 Study InvestigatorsThe treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care200326113080308614578243
   PubMed Web of Science ®Google Scholar
• SwinnenSGSimonACHollemanFHoekstraJBDevriesJHInsulin detemir versus insulin glargine for type 2 diabetes mellitusCochrane Database Syst Rev20117CD006383
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial InvestigatorsGersteinHCBoschJDagenaisGRBasal insulin and cardiovascular and other outcomes in dysglycemiaN Engl J Med2012367431932822686416
   PubMed Web of Science ®Google Scholar
• Russell-JonesDGallMANiemeyerMDiamantMDel PratoSInsulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trialsNutr Metab Cardiovasc20152510898905
   Web of Science ®Google Scholar
• GoldmanJWhiteJRNew insulin glargine 300 U/mL for the treatment of type 1 and type 2 diabetes mellitusAnn Pharmacother201549101153116126238470
   PubMed Web of Science ®Google Scholar
• BunckMCDiamantMCornerAOne-year treatment with exenatide improves beta-cell function, compared with basal insulin, in metformin treated type 2 diabetic patients: a randomized, controlled trialDiabetes Care200932576276819196887
   PubMed Web of Science ®Google Scholar
• BarnettAHBurgerJJohnsDTolerability and efficacy of exenatide and titrated basal insulin in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trialClin Ther200729112333234818158075
   PubMed Web of Science ®Google Scholar
• Russell-JonesDVaagASchmitzOLiraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study GroupLiraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia200952102046205519688338
   PubMed Web of Science ®Google Scholar
• BunckMCCornerAEliassonBOne-year treatment with exenatide versus basal insulin: effects on postprandial glycemia, lipid profiles, and oxidative stressAtherosclerosis2010212122322920494360
   PubMed Web of Science ®Google Scholar
• MathieuCOstensonCGMatthaeiSUsing exenatide twice daily or insulin in clinical practice: results from CHOICEDiabetes Ther20134228530824018835
   PubMed Web of Science ®Google Scholar
• DiamantMVan GaalLGuerciBExenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trialLancet Diabetes Endocrinol20142646447324731672
   PubMed Web of Science ®Google Scholar
• UccellatoreAGenoveseSDicembriniIMannucciECerielloAComparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonistsDiabetes Ther20156323925626271795
   PubMed Web of Science ®Google Scholar
• EngCKramerCKZinmanBRetnakaranRGlucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysisLancet201438499612228223425220191
   PubMed Web of Science ®Google Scholar
• MeierJJRosenstockJHincelin-MéyAContrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trialDiabetes Care20153871263127325887358
   PubMed Web of Science ®Google Scholar
• BuseJBBergenstalRMGlassLCUse of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trialAnn Intern Med2011154210311221138825
   PubMed Web of Science ®Google Scholar
• DiamantMNauckMAShaginianR4B Study GroupGlucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetesDiabetes Care201437102763277325011946
   PubMed Web of Science ®Google Scholar
• MathieuCRodbardHWCariouBBEGIN: VICTOZA ADD-ON (NN1250-3948) study groupA comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)Diabetes Obes Metab201416763664424443830
   PubMed Web of Science ®Google Scholar
• AhmannARodbardHWRosenstockJNN2211-3917 Study GroupEfficacy and safety of liraglutide vs. placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trialDiabetes Obes Metab201517111056106426179619
   PubMed Web of Science ®Google Scholar
• BuysmanEKLiuFHammerMLangerJImpact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort studyAdv Ther201532434135525832470
   PubMed Web of Science ®Google Scholar
• WeiWPanCXieLBaserOReal-world insulin treatment persistence among patients with type 2 diabetes: measures, predictors and outcomesEndocr Pract2014201526124013990
   PubMed Web of Science ®Google Scholar
• LevinPWeiWWangLPanCDouglasDBaserOCombination therapy with basal insulin and exenatide: real-world outcomes in patients with type 2 diabetesCurr Med Res Opin201228318
   Web of Science ®Google Scholar
• LevinPWeiWWangLBrombergerLAClinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitusEndocr Pract2012181172521742605
   PubMed Web of Science ®Google Scholar
• CDC.govCenters for Disease Control and Prevention International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)Atlanta, GA2015 Available from: www.cdc.gov/nchs/icd/icd9cm.htmAccessed June 14, 2016
   Google Scholar
• MarsoSPDanielsGHBrown-FrandsenKLiraglutide and cardiovascular outcomes in type 2 diabetesN Engl J Med2016375431132227295427
   PubMed Web of Science ®Google Scholar
• ArnoldsSDellwegSClairJFurther improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with basal insulin and metformin: a proof-of-concept studyDiabetes Care20103371509151520357372
   PubMed Web of Science ®Google Scholar
• RiddleMCAronsonRHomePAdding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)Diabetes Care20133692489249623628617
   PubMed Web of Science ®Google Scholar
• de WitHMVervoortGMJansenHJde GrauwWJde GalanBETackCJLiraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)Diabetologia20145791812181924947583
   PubMed Web of Science ®Google Scholar
• BalenaRHensleyIEMillerABarnettAHCombination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literatureDiabetes Obes Metab201315648550223061470
   PubMed Web of Science ®Google Scholar
• BuseJBNauckMForstTExenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyLancet2013381986111712423141817
   PubMed Web of Science ®Google Scholar
• TrujilloJMNufferWEllisSLGLP-1 receptor agonists: a review of head-to-head clinical studiesTher Adv Endocrinol Metab201561192825678953
   PubMed Web of Science ®Google Scholar
• UngerJUncovering undetected hypoglycemic eventsDiabetes Metab Syndr Obes20125577422563248
   PubMedGoogle Scholar
• AndersonSLTrujilloJMLixisenatide in type 2 diabetes: latest evidence and clinical usefulnessTher Adv Chronic Dis20167141726770666
   PubMed Web of Science ®Google Scholar
• MoghissiESTreating patients with diabetes of long duration: GLP-1 receptor agonists and insulin in combinationJ Am Osteopath Assoc20141145 Suppl 2S22S2924769505
   PubMedGoogle Scholar